Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer

JI Peng

doi:10.19401/j.cnki.1007-3639.2018.12.008

您当前的位置：

首页 >

文章列表页 >

Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer

更新时间：2026-01-27

- Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer
- China Oncology Vol. 28, Issue 12, Pages: 928-934(2018)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，上海市乳腺肿瘤重点实验室，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.12.008
  CLC：
- Published Online：11 January 2019，
  
  Published：11 January 2019
- 稿件说明：
移动端阅览
吉芃,龚悦,狄根红. 肿瘤浸润淋巴细胞在三阴性乳腺癌和HER2阳性乳腺癌中作用的最新研究进展[J]. 中国癌症杂志, 2018, 28(12): 928-934.

JI Peng. Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer[J]. China Oncology, 2018, 28(12): 928-934.
吉芃,龚悦,狄根红. 肿瘤浸润淋巴细胞在三阴性乳腺癌和HER2阳性乳腺癌中作用的最新研究进展[J]. 中国癌症杂志, 2018, 28(12): 928-934. DOI： 10.19401/j.cnki.1007-3639.2018.12.008.

JI Peng. Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer[J]. China Oncology, 2018, 28(12): 928-934. DOI： 10.19401/j.cnki.1007-3639.2018.12.008.

摘要

在乳腺癌的所有亚型中，三阴性乳腺癌（triple-negative breast cancer，TNBC）和人表皮生长因子受体2（human epidermal growth factor receptor 2 ，HER2）阳性型乳腺癌的恶性程度较高，越来越多的证据提示这两种亚型肿瘤病灶中肿瘤浸润淋巴细胞（tumor-infiltrating lymphocytes，TIL）所占百分比越高，患者的预后越好。但TIL并非单一种类细胞，其复杂的内部细胞成分导致在不同亚型乳腺癌患者或接受不同治疗的乳腺癌患者中，发挥的预后预测作用差异较大。本文就TIL的分类，TIL在TNBC、HER2阳性乳腺癌中的作用和TIL相关免疫治疗策略的最新研究进展作一总结。

Abstract

Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2)-positive breast cancer are the most aggressive subtypes of breast cancer with higher recurrent rates

distant metastasis rates and poor prognosis. There are increasing evidence suggesting that high level of tumor-infiltrating lymphocytes (TIL) is associated with a more favorable outcome. However

the complex cellular components within TIL have an enormous influence on the prognostic value of TIL in patients with various subtypes or patients receiving different therapies. In this review

we summarized the classification of TIL

the value of TILs in TNBC and HER2-positive breast cancer and immunotherapies related to TIL.

关键词

Keywords

references

Views

3975

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The progress of treatment for triple-negative breast cancer in the era of precision medicine

The effect of lung stereotactic body radiotherapy on peripheral blood lymphocytes

Research progress of breast tumor microenvironment-targeted therapy

Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation

Related Author

CAO Xiaoshan

CONG Binbin

GE Hong

JIANG Yue

LIU Xiao

CUI Yingying

GUO Leiming

XU Wencai

Related Institution

Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science

Department of Radiotherapy, the Affiliated Cancer Hospital of Zhengzhou University

复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系

Department of Cell Biology and Genetics, Chongqing Medical University

AI问答

⁰